THE IMPACT OF TRIMETAZIDINE ON THE ANTHROPOMETRIC PARAMETERS OF DOXORUBICIN-CYCLOPHOSPHAMIDE MODE IN CHEMOTHERAPY-INDUCED HEART ALTERATION.

The field of cardio-oncology encompasses the CVD preventive activities and management among under-treatment and post-treatment cancer patients. Cardiovascular complications of cancer therapy manifest because of a tremendous potential of chemotherapy-driven cardiotoxicity. Cardiotoxicity implies structural and functional myocardial alteration, in conjunction with the sensitive cardiac biomarkers (namely, troponins T and I, and NT-pro-BNP) concentration increase, as well as the subclinical or clinical decrease of the left ventricular ejection fraction. In our study, we assess the anthropometric parameters of heart affected by doxorubicin and cyclophosphamide (AC)-mode of chemotherapy. As an object of study, 120 males of inbred rats weighing 280-300 gr of the Wistar line are involved. Course duration 14 days. Course dosage of doxorubicin hydrochloride was 15 mg/kg, cyclophosphamide monohydrate - 150 mg/kg, trimetazidinedihydrochloride - 42 mg/kg. The body weight, heart weight and heart/body ratio were assessed. The results of our study the normalization of the heart weight in group No. 3, should be consider as an indicator of successful cardioprotection. Thus, our study demonstrated a statistically significant and pathogenetically valuable morpho-stabilizing potential of TMZ. Analyzed the TMZ-induced stabilization of heart weight, body weight and heart/weight ratio parameters during AC-mode of chemotherapy mediated model of heart alteration, the TMZ administration should be considered as real acting pharmacological agent which is able to preserve myocardium from pathological deviations.